IMVT — Immunovant Cashflow Statement
0.000.00%
Last trade - 00:00- $2.50bn
- $2.13bn
Annual cashflow statement for Immunovant, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -66.4 | -107 | -157 | -211 | -259 |
| Depreciation | |||||
| Non-Cash Items | 8.2 | 19.5 | 35.4 | 33.4 | 42.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.81 | 4.57 | 15.1 | -10.9 | 2.63 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -53.4 | -83.3 | -106 | -188 | -214 |
| Capital Expenditures | -0.031 | -0.21 | -0.254 | -0.197 | -0.36 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.031 | -0.21 | -0.254 | -0.197 | -0.36 |
| Financing Cash Flow Items | 109 | -0.14 | 200 | -0.272 | -6.01 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 147 | 383 | 200 | 70.9 | 472 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 93.6 | 300 | 93.7 | -117 | 259 |